Measur ing brain tumor growth: Combined bioluminescence imaging-magnetic resonance imaging strategy

Molecular Imaging

Volumn 8, Issue 5, 2009, Pages 245-253

  Jost, Sarah C ^a   Collins, Lynne ^a   Travers, Sarah ^a   Piwnica Worms, David ^a   Garbow, Joel R ^a  

^a University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLUMINESCENCE IMAGING; BRAIN TUMORS; GLIOBLASTOMAS; HIGH-THROUGHPUT; IN-VIVO MEASUREMENT; LIMITED CAPACITY; MOUSE MODELS; MULTI-MODALITY; PRECLINICAL STUDIES; SMALL-ANIMAL; THERAPEUTIC INTERVENTION; THERAPEUTIC STRATEGY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MODELS; TUMOR VOLUMES; VOLUMETRIC MEASUREMENT;

ANIMALS; BIOLUMINESCENCE; BRAIN MODELS; LIGHT EMISSION; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; ONCOLOGY; PHOSPHORESCENCE;

TUMORS;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BRAIN TUMOR; DIAGNOSTIC IMAGING; FEMALE; GLIOBLASTOMA; LUMINESCENCE; METHODOLOGY; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FEMALE; GLIOBLASTOMA; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C;

EID: 70349653907     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2009.00023     Document Type: Article

References (45)

1. Jost S. C., Wanebo JE, Song SK, et al. Small animal imaging as a tool for in vivo monitoring in a murine model for glioblastoma. Neurosurgery 2007; 60: 360-70.
2. Nelson A, Algon S, Munasinghe J, et al. Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol 2003; 62: 259-67.
3. Rhemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000; 2: 491-5.
4. Szentirmai O, Baker CH, Lin N, et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006;58:365-72.
5. Kwon C. H., Zhao D, Chen J, et al. Pten haploinsuffi ciency accelerates formation of high-grade astrocytomas. Cancer Res 2008;68:3286-94.
6. McConville P, Hambardzumyan D, Moody JB, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res 2007; 13: 2897-904.
7. Zhu Y, Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 8: 119-30.
8. Adzamli K, Yablonskiy DA, Chicoine MR, et al. Albuminbinding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. Magn Reson Med 2003;49:586-90.
9. Bock N. A., Zadeh G, Davidson LM, et al. High-resolution longitudinal screening with magnetic resonance imaging on a murine brain cancer model. Neoplasia 2003;5:546-54.
10. Rustamzadeh E, Hall WA, Todhunter D, et al. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int J Cancer 2006;118:2594-601.
11. Schmidt K. F., Ziu M, Schmidt NO, et al. Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol 2004;68:207-15.
12. Sherburn E. W., Wanebo JE, Kim P, et al. Gliomas in rodent whisker barrel cortex: a new tumor model. J Neurosurg 1999;91:814-21.
13. Chenevert T. L., Stegman LD, Taylor JM, et al. Diffusion MRI: early surrogate marker of therapeutic effi cacy. J Natl Cancer Inst 2000;92:2029-36.
14. Hall D. E., Moffat BA, Stojanovska J, et al. Therapeutic effi cacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004; 10: 7852-9.
15. Moffat B. A., Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for stratifi cation of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524-9.
16. Yablonskiy D. A., Bretthorst GL, Ackerman JJH. Statistical model for diffusion attenuated MR signal. Magn Reson Med 2003;50:664-9.
17. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14:6580-9.
18. Barrett T, Brechbiel M, Bernardo M, et al. MRI of tumor angiogenesis. J Magn Reson Imaging 2007; 26: 235-49.
19. Huang W, Li X, Morris EA, et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci U S A 2008;105:17943-8.
20. Jackson A, O'Connor JP, Parker GJ, et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13:3449-59.
21. Knopp M. V., Giesel FL, Marcos H, et al. Dynamic contrastenhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001; 12: 301-8.
22. Bernsen HJJA, Heerschap A, Kogel AJ, et al. Image-guided 1H NMR spectroscopical and histological characterization of a human brain tumor model in the nude rat; a new approach to monitor changes in tumor metabolism. J Neurooncol 1992;13:119-30.
23. Howe F. A., Barton SJ, Cudlip SA, et al. Metabolic profi les of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223-32.
24. Contag C. H., Jenkins D, Contag P, et al. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000;2:41-51.
25. Edinger M, Cao YA, Hornig YS, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002; 38: 2128-36.
26. Jenkins D. E., Hornig YS, Oei Y, et al. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005;7:R444-54.
27. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 2005;7:5-15.
28. Paroo Z, Bollinger RA, Braasch DA, et al. Validating bioluminescence imaging as a high throughput, quantitative modality for assessing tumor burden. Mol Imaging 2004; 3: 117-24.
29. Soling A, Rainov NG. Biouminescence imaging in vivo: application to cancer research. Expert Opin Biol Ther 2003;3:1163-72.
30. Rubin J. B., Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003;100:13513-8.
31. Soling A, Theiss C, Jungmichel S, et al. A dual function fusion protein of herpes simplex virus type 1 thymidine kinase and fi refl y luciferase for noninvasive in vivo imaging of gene therapy in malignant glioma. Genet Vaccines Ther 2004; 2: 7.
32. Dinca E. B., Sarkaria JN, Schroeder MA, et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg 2007;107:610-6.
33. Yuan L, Siegel M, Choi K, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fi bronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007;26:2563-73.
34. Goldhoff P, Warrington NM, Limbrick DD Jr, et al. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res 2008;14:7717-25.
35. Gross S, Piwnica-Worms D. Monitoring proteasome activity in cellulo and in living animals by bioluminescent imaging: technical considerations for design and use of genetically encoded reporters. Methods Enzymol 2005;399:512-30.
36. Cornelissen B, Kersemans V, Staelens J, et al. Comparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice. Br J Radiol 2005;78:338-42.
37. Edinger M, Sweeney TJ, Tucker AA, et al. Non-invasive assessment of tumor proliferation in animal models. Neoplasia 1999;1:303-10.
38. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004;10:1257-60.
39. Vooijs M, Jonkers J, Lyons S, et al. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 2002;62:1862-7.
40. Zhao D, Richer E, Antich PP, et al. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confi r med by MRI. FASEB J 2008; 22: 2445-51.
41. Contag C. H., Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 2002;4:235-60.
42. Sarraf-Yazdi S, Mi J, Dewhirst MW, et al. Use of in vivo bioluminescence imaging to predict hepatic tumor burden in mice. J Surg Res 2004;120:249-55.
43. Piwnica-Worms D, Schuster DP, Garbow JR. Molecular imaging of host-pathogen interactions in intact small animals. Cell Microbiol 2004; 6: 319-31. (Pubitemid 38379815)
44. El Hilali N, Rubio N, Blanco J. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase. Clin Cancer Res 2005; 11: 1253-8.
45. Brutkiewicz S, Mendonca M, Stantz K, et al. The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging. Luminescence 2007;122:221-8.